Vertex Pharmaceuticals reports $3.44 billion revenue for quarter ended September 30, 2026, up 11.8%
Vertex Pharmaceuticals reported revenue of $3.44 billion for the quarter ended September 30, 2026, an increase of 11.8% from the same quarter a year earlier ($3.08 billion).
For the same period it posted net income of $653.6 million, down 39.6%, or $2.56 per diluted share (4.20 a year earlier).
That is a net margin of 19%.
On Sanad's AAOIFI Standard 21 screen, Vertex Pharmaceuticals is currently compliant: interest-bearing debt is 3.3% of market capitalisation (limit 30%), and impure income is 4.1% of revenue (limit 5%).
Is Vertex Pharmaceuticals halal?
See the full AAOIFI screening of Vertex Pharmaceuticals
See the full AAOIFI screening of Vertex Pharmaceuticals
Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 3, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.